Chemomab Therapeutics Ltd. cotiza a 1.24 USD y tiene una capitalización bursátil de $9M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of maj…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | — | — | — | $-0.02 |
| Estimado | — | $-0.01 | $-0.04 | $-0.04 |
| Sorpresa | — | — | — | +50.0% |
| Métrica | CMMB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -72.9% | -40.4% | -32.5% |
| ROA | -65.1% | -32.0% | -33.1% |
| Current Ratio | 9.08 | 2.84 | +6.24 |
| Debt / Equity | — | 0.28 | — |